Cargando…

A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma

OBJECTIVE: The proportion of patients with stage I lung adenocarcinoma (LUAD) has dramatically increased with the prevalence of low-dose computed tomography use for screening. Up to 30% of patients with stage I LUAD experience recurrence within 5 years after curative surgery. A robust risk stratific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Chengming, Wang, Sihui, Zheng, Sufei, Wang, Xinfeng, Huang, Jianbin, Lei, Yuanyuan, Mao, Shuangshuang, Feng, Xiaoli, Sun, Nan, He, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330534/ https://www.ncbi.nlm.nih.gov/pubmed/33856140 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0397

Ejemplares similares

Development and external validation of a composite immune-clinical prognostic model associated with EGFR mutation in East-Asian patients with lung adenocarcinoma
por: Liu, Chengming, et al.
Publicado: (2021)

S100A7 as a potential diagnostic and prognostic biomarker of esophageal squamous cell carcinoma promotes M2 macrophage infiltration and angiogenesis
por: Lu, Zhiliang, et al.
Publicado: (2021)

PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing
por: Mao, Shuangshuang, et al.
Publicado: (2019)

Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific immune and metabolic state
por: Huang, Jianbing, et al.
Publicado: (2020)

Combined detection of aneuploid circulating tumor‐derived endothelial cells and circulating tumor cells may improve diagnosis of early stage non‐small‐cell lung cancer
por: Lei, Yuanyuan, et al.
Publicado: (2020)

Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis
por: Zhu, Mingchuang, et al.
Publicado: (2022)

The TGFβ-Induced Long Non-coding RNA TBULC Promotes the Invasion and Migration of Non-small Cell Lung Cancer Cells and Indicates Poor Prognosis
por: Zheng, Sufei, et al.
Publicado: (2019)

Corrigendum: Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis
por: Zhu, Mingchuang, et al.
Publicado: (2022)

Exosomal miR-141 promotes tumor angiogenesis via KLF12 in small cell lung cancer
por: Mao, Shuangshuang, et al.
Publicado: (2020)

Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1
por: Mao, Shuangshuang, et al.
Publicado: (2021)

The membrane-bound and soluble form of melanotransferrin function independently in the diagnosis and targeted therapy of lung cancer
por: Lei, Yuanyuan, et al.
Publicado: (2020)

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

S100A7 attenuates immunotherapy by enhancing immunosuppressive tumor microenvironment in lung squamous cell carcinoma
por: Liu, Chengming, et al.
Publicado: (2022)

ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells
por: lei, Yuanyuan, et al.
Publicado: (2020)

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer
por: Jin, Runsen, et al.
Publicado: (2020)

Translational value of IDH1 and DNA methylation biomarkers in diagnosing lung cancers: a novel diagnostic panel of stage and histology-specificity
por: Zang, Ruochuan, et al.
Publicado: (2019)

Avoiding Absolute Quantification Trap: A Novel Predictive Signature of Clinical Benefit to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer
por: Liu, Chengming, et al.
Publicado: (2021)

Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection
por: Zang, Ruochuan, et al.
Publicado: (2019)

The average copy number variation (CNVA) of chromosome fragments is a potential surrogate for tumor mutational burden in predicting responses to immunotherapy in non‐small‐cell lung cancer
por: Lei, Yuanyuan, et al.
Publicado: (2021)

Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

Correction: Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer
por: Liu, Chengming, et al.
Publicado: (2022)

TGF-β-induced PLEK2 promotes metastasis and chemoresistance in oesophageal squamous cell carcinoma by regulating LCN2
por: Wang, Feng, et al.
Publicado: (2021)

Surgical management of periampullary adenocarcinoma: defining an optimal prognostic lymph node stratification schema
por: He, Chaobin, et al.
Publicado: (2018)

Risk stratification model for patients with stage I invasive lung adenocarcinoma based on clinical and pathological predictors
por: Wang, Yiyang, et al.
Publicado: (2021)

Prognostic Stratification According to Size and Dominance of Radiologic Solid Component in Clinical Stage IA Lung Adenocarcinoma
por: Nakao, Masayuki, et al.
Publicado: (2022)

Genetic and immunologic features of recurrent stage I lung adenocarcinoma
por: Kratz, Johannes R., et al.
Publicado: (2021)

Histologic subtyping in pathologic stage I-IIA lung adenocarcinoma provides risk-based stratification for surveillance
por: Takahashi, Yusuke, et al.
Publicado: (2018)

Coupled immune stratification and identification of therapeutic candidates in patients with lung adenocarcinoma
por: Hu, Weilei, et al.
Publicado: (2020)

Prognostic relevance of TTF-1 expression in stage I adenocarcinoma
por: Zhou, Chao, et al.
Publicado: (2017)

Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy
por: Park, Inkeun, et al.
Publicado: (2016)

Identification of recurrence-associated microRNAs in stage I lung adenocarcinoma
por: Sim, Jongmin, et al.
Publicado: (2018)

Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves Diagnosis and Prognostic Stratification
por: Fernández Moro, Carlos, et al.
Publicado: (2016)

Identification of four differentially methylated genes as prognostic signatures for stage I lung adenocarcinoma
por: Luo, Wei-Ming, et al.
Publicado: (2018)

The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification
por: Guan, Jun, et al.
Publicado: (2018)

Hallmark guided identification and characterization of a novel immune-relevant signature for prognostication of recurrence in stage I–III lung adenocarcinoma
por: Zhang, Yongqiang, et al.
Publicado: (2022)

Correction: Immunohistochemical Typing of Adenocarcinomas of the Pancreatobiliary System Improves Diagnosis and Prognostic Stratification
por: Fernández Moro, Carlos, et al.
Publicado: (2017)

HOXB13 and TFF3 can contribute to the prognostic stratification of prostate adenocarcinoma
por: Timofte, Andrei Daniel, et al.
Publicado: (2021)

Robust deep learning model for prognostic stratification of pancreatic ductal adenocarcinoma patients
por: Ju, Jie, et al.
Publicado: (2021)

Prognostic significance of centrosomal protein 55 in stage I pulmonary adenocarcinoma after radical resection
por: Jiang, Wenpeng, et al.
Publicado: (2016)

Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma
por: He, Ying, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0r46b9u37vp0at808mudk8tjta